Newsroom

Sorted by: Latest

-

エナジー・インパクト・パートナーズ、エネルギー革新と脱炭素化を推進するために、シンガポール経済開発庁との提携を強化

ニューヨーク&シンガポール--(BUSINESS WIRE)--(ビジネスワイヤ) -- 世界的なエネルギー投資会社であるエナジー・インパクト・パートナーズ(EIP)とシンガポール経済開発庁(EDB)は、シンガポールにおけるエネルギー革新と脱炭素化の推進を支援すべく、両者の提携関係をさらに強化すると発表しました。この発表は、EDB、シンガポール科学技術研究庁(A*STAR)、および先端エネルギー・脱炭素化オフィス(AEDO)が主催する「第1回シンガポール産業脱炭素化フォーラム2026」の会場で行われました。 シンガポールの研究基盤、産業インフラ、そしてアジア全域にわたるコネクティビティは、エネルギー・産業企業や協業するテック系スタートアップ企業に跨るEIPのグローバルリーチを補完するものです。これらの強みが相まって、研究開発、実証実験、スケールアップから商用展開に至る、イノベーションの全プロセスを支えています。 EIPは、将来性のある企業をシンガポールのイノベーション環境と結びつけ、現地の研究・産業エコシステム間の技術交流や戦略的連携の道を開きます。また、両組織はそれぞれのネットワー...
-

KBRA Assigns Preliminary Ratings to BHG Securitization Trust 2026-3CON

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to five classes of notes issued by BHG Securitization Trust 2026-3CON (“BHG 2026-3CON”), an asset-backed securitization collateralized by a pool of unsecured consumer loans (“Consumer Loans”). BHG 2026-3CON will issue five classes of notes totaling $396.72 million. BHG 2026-3CON has initial credit enhancement levels of 48.00% for the Class A notes to 1.50% for the Class E notes. Initial credit enhancement consists of subordination of j...
-

Antares Clears First DOE Authorization Gate for Mark-1, Its Electricity-Producing Reactor

TORRANCE, Calif.--(BUSINESS WIRE)--Antares today announced that the U.S. Department of Energy (DOE) has approved the Nuclear Safety Design Agreement (NSDA) for Mark-1, the company's first electricity-producing reactor. The approval is the first step in DOE's authorization pathway for Mark-1 and establishes the design requirements, safety analysis approach, and regulatory expectations that will govern the reactor through construction and operation. Mark-1 is designed to operate at full electrica...
-

Green Plains to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026

OMAHA, Neb.--(BUSINESS WIRE)--Green Plains Inc. (NASDAQ:GPRE) will release third quarter 2026 financial results after the market closes on November 5, 2026, and then host a conference call beginning at 4:30 p.m. Eastern time (3:30 p.m. Central time) to discuss the results and outlook. Domestic and international participants can access the conference call by dialing 833.461.5787 and 585.542.9983, respectively, and referencing conference ID 198456298. Participants are advised to call at least 10...
-

JACQUET METALS SA : PROGRAMME DE RACHAT DE TITRES

SAINT-PRIEST, France--(BUSINESS WIRE)--Regulatory News: Déclaration des transactions sur actions propres Période du 14 au 20 octobre 2026 Émetteur : JACQUET METALS S.A. (LEI : 969500V8OL3NGL0GKZ37) (Paris:JCQ) Catégories de titres : actions ordinaires (ISIN : FR0000033904) Descriptif du programme mis en ligne sur le site Internet de l’Autorité des Marchés Financiers le 26 juin 2026. Achats réalisés au cours de la période 1 Dates des transactions 2 Nombres de titres achetés (*) 3 Prix moyens uni...
-

Securities Fraud Lawsuit Filed Against D-Wave Quantum, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline

LOS ANGELES--(BUSINESS WIRE)--A securities class action lawsuit has been filed against D-Wave Quantum, Inc. ("D-Wave" or the "Company") (NASDAQ: QBTS) on behalf of investors who purchased or otherwise acquired D-Wave Quantum, Inc. securities from February 26, 2026 to August 25, 2026, inclusive. The Law Offices of Frank R. Cruz today reported the case, Fessler v. D-Wave Quantum, Inc. et al., filed on October 15, 2026 in the U.S. District Court California Northern District (Case No. 3:26-cv-11953...
-

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab. The trial met its primary endpoint of progression-free survival...
-

New WSIB premium cuts are a further insult while layoffs harm services for injured workers

TORONTO--(BUSINESS WIRE)--Workers at the Workplace Safety and Insurance Board (WSIB) are shocked at the Ontario government’s decision to further reduce WSIB premium rates for bosses while injured workers continue to face the consequences of long-standing cuts to their compensation and WSIB’s own employees face needless layoffs. “Let’s be clear about who is paying the price for these anti-worker decisions,” said Harry Goslin, president of Ontario Compensation Employees’ Union (OCEU)/CUPE Local 1...
-

Citibank UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  Re: Macquarie Bank Ltd Australia.   EUR 300,000,000.00   MATURING: 27-Jan-2028   ISIN: XS3280329452     PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 27-Oct-2026 TO 27-Jan-2027 HAS BEEN FIXED AT 2.99 PCT   DAY BASIS: ACTUAL/360   INTEREST PAYABLE VALUE 27-Jan-2027 WILL AMOUNT TO: EUR 2,289,266.67 PER EUR 300,000,000.00 DENOMINATION  ...
-

AM Best Revises Outlooks to Stable for Members of Coverys Companies

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has revised the outlooks to stable from negative and affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a” (Excellent) of Medical Professional Mutual Insurance Company (Boston, MA) and its rating unit members, collectively known as Coverys Companies (Coverys). (See below for a detailed list of these subsidiaries and Credit Ratings [ratings]).The ratings reflect Coverys’ balance sheet st...